Novel bactericidal antibodies against Neisseria meningitidis serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.

 
Web www.patentalert.com

< Determining prognosis of colon or breast cancer by measuring TTK expression

> Methods and devices relating to estimating classifier performance

> Estimating fluidic properties and using them to improve the precision/accuracy of metered fluids and to improve the sensitivity/specificity in detecting failure modes

~ 00505